New drug combo aims to extend life for blood cancer patients

NCT ID NCT06104566

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times

Summary

This study tests whether adding a new drug, lisaftoclax, to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma live longer without their cancer getting worse. About 400 adults who have already been treated with a BTK inhibitor will be randomly assigned to receive either the combination or continue their current therapy alone. The goal is to see if the combination improves outcomes while keeping side effects manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLL/SLL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kaluga Regional Clinical Research
RECRUITING

Kaluga, 246007, Russia

Contact
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact

Conditions

Explore the condition pages connected to this study.

CLL/SLL